Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SRNE > SEC Filings for SRNE > Form 8-K on 11-Mar-2014All Recent SEC Filings

Show all filings for SORRENTO THERAPEUTICS, INC.

Form 8-K for SORRENTO THERAPEUTICS, INC.


11-Mar-2014

Change in Directors or Principal Officers, Other Events, Financial St


Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 7, 2014, the Company appointed Mark Durand as a director of the Company, as Chairman of the Audit Committee, and as a member of the Compensation Committee.

Mr. Durand has nearly 28 years of broad pharmaceutical industry experience in a variety of leadership roles for both branded and generic drugs. Currently, Mr. Durand is an independent strategic consultant for pharmaceutical firms. Previously, he was the Chief Financial Officer and Senior Vice President Finance and Business Development for Watson Pharmaceuticals (now Actavis). Prior to that, he was Senior Vice President of Finance and Business Development at Teva Americas and served under William Marth, currently chairman of Sorrento's Board of Directors. Mr. Durand began his career at Bristol-Myers Squibb in 1986 and he held the position of Vice President of Finance and Business Development. He received a bachelor's degree from Duke University, a master's of science degree from Dartmouth College, and a master's of business administration degree from the University of Chicago.

On March 7, 2014, Scott Salka resigned as a director of the Company to devote his time to a company he founded recently.



Item 8.01 Other Items.

On March 11, 2014, the Company issued a press release regarding the appointment of Mark Durand as director and the resignation of Scott Salka as a director of the Company.

The information in this Item 8.01, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1933, as amended, or otherwise subject to the liabilities of that section.



Item 9.01 Financial Statements and Exhibits.

Exhibit No. Description

99.1 Press release dated March 11, 2014.


  Add SRNE to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SRNE - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.